Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1372860 | Bioorganic & Medicinal Chemistry Letters | 2009 | 5 Pages |
Abstract
Vasopressin 1b (V1b) antagonists have been postulated as possible treatments for depression and anxiety. A novel series of potent and selective V1b antagonists has been identified starting from an in-house screen hit. The incorporation of a sulfonamide linker between a tetrahydroisoquinoline core and amino piperidine lead to the identification of a V1b antagonist with similar affinity for human and rat receptors. Further optimization of the right hand portion afforded potent V1b antagonists that possessed moderate to high selectivity over other receptors.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Jack D. Scott, Michael W. Miller, Sarah W. Li, Sue-Ing Lin, Henry A. Vaccaro, Liwu Hong, Deborra E. Mullins, Mario Guzzi, Jay Weinstein, Robert A. Hodgson, Geoffrey B. Varty, Andrew W. Stamford, Tin-Yau Chan, Brian A. McKittrick, William J. Greenlee,